Abstract:Neisseria gonorrhoeae is a major public health concern because of the high incidence of gonorrhea and the increasingly limited options for antimicrobial therapy. Strains associated with the FC428 clone are a particular concern because they have shown global dissemination and they display high-level resistance against the currently recommended ceftriaxone therapy. ABSTRACT Alternative antimicrobial therapies are urgently required for the multidrug-resistant bacterial pathogen Neisseria gonorrhoeae, for which currently ceftriaxone is the only remaining recommended first-line therapy. Repurposing of drugs that are approved for other clinical applications offers an efficient approach for development of alternative antimicrobial therapies. Auranofin, cannabidivarin, and tolfenamic acid were recently identified to display antimicrobial activity against N. gonorrhoeae. Here, we investigated their activity against a collection of 575 multidrug-resistant clinical isolates. All three compounds displayed consistent antimicrobial activity against all isolates, including against strains associated with the high-level ceftriaxone-resistant FC428 clone, with both the mode and MIC90 for auranofin of 0.5 mg/L, while both the mode and MIC90 for cannabidivarin and tolfenamic acid were 8 mg/L. Correlations between MICs of ceftriaxone and auranofin, cannabidivarin or tolfenamic acid were low, indicating that development of cross-resistance is unlikely. Furthermore, antimicrobial synergy analysis between ceftriaxone and auranofin, cannabidivarin, or tolfenamic acid by determination of the fractional inhibitory concentration index (FICI) resulted in an interpretation of indifference. Finally, time-kill analyses showed that all three compounds are bactericidal against both the N. gonorrhoeae ATCC 49226 reference strain and an FC428-associated clinical isolate, with particularly cannabidivarin displaying rapid bactericidal activity. Overall, auranofin, cannabidivarin, and tolfenamic acid displayed consistent antimicrobial activity against multidrug-resistant N. gonorrhoeae, warranting further exploration of their suitability as alternative antimicrobials for treatment of gonococcal infections. IMPORTANCE Neisseria gonorrhoeae is a major public health concern because of the high incidence of gonorrhea and the increasingly limited options for antimicrobial therapy. Strains associated with the FC428 clone are a particular concern because they have shown global dissemination and they display high-level resistance against the currently recommended ceftriaxone therapy. Therefore, development of alternative antimicrobial therapies is urgently required to ensure treatment of gonorrhea remains available in the future. Repurposing of clinically approved drugs could be a rapid approach for the development of such alternative antimicrobials. In this study, we showed that repurposing of auranofin, cannabidivarin, and tolfenamic acid for antimicrobial therapy of gonorrhea deserves further clinical explorations because these compounds displayed consistent antimicrobial activity against a large collection of contemporary multidrug-resistant gonococcal isolates that included strains associated with the FC428 clone.

High Percentage Of The Ceftriaxone-Resistant Neisseria Gonorrhoeae Fc428 Clone Among Isolates From A Single Hospital In Hangzhou, China

High percentage of the ceftriaxone-resistant<i>Neisseria gonorrhoeae</i>FC428 clone among isolates from a single hospital in Hangzhou, China

High-level Ceftriaxone Resistance Due to Transfer of Pena Allele 60.001 into Endemic Gonococcal Lineages in Hangzhou, China.

Increasing prevalence of Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone and resistance to azithromycin in Hangzhou, China (2015-17).

Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China.

Identification of High-Level Ceftriaxone-Resistant Neisseria Gonorrhoeae Isolates with Diverse Pena Alleles in Zhejiang, China.

Antibiotic Resistance and Treatment Options for Multidrug-Resistant Gonorrhea

Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid Against Multidrug-Resistant Neisseria Gonorrhoeae

Bacitracin Enhances Ceftriaxone Susceptibility of the High-Level Ceftriaxone-Resistant Gonococcal FC428 Clone

Impact of the Gonococcal FC428 Pena Allele 60.001 on Ceftriaxone Resistance and Biological Fitness.

Adaptability analysis of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in China

Identification of Ceftriaxone-Resistant Neisseria Gonorrhoeae FC428 Clone and Isolates Harboring a Novel Mosaic Pena Gene in Chengdu in 2019–2020

Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone

Determination of Fusidic Acid Susceptibility of Multidrug-resistant Gonococcal Isolates from China

Linezolid-Resistant Clinical Isolates of Meticillin-Resistant Coagulase-Negative Staphylococci and Enterococcus Faecium from China

Genomic Epidemiology of Neisseria Gonorrhoeae in Shenzhen, China, During 2019–2020: Increased Spread of Ceftriaxone-Resistant Isolates Brings Insights for Strengthening Public Health Responses

Th1-polarized MtrE-based Gonococcal Vaccines Display Prophylactic and Therapeutic Efficacy.

Neisseria gonorrhoeae ST-1901 in Rio de Janeiro from 2006 to 2022: Phylogeny and antimicrobial resistance evolution of a well-succeeded pathogen

Molecular characteristics of cephalosporins resistant Neisseria gonorrhoeae strains isolated from Gonococcal Antimicrobial Resistance Surveillance Program in China, 2015-2016

Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015 to 2024; an observational study

Antimicrobial Resistance and Molecular Characteristics among Neisseria Gonorrhoeae Clinical Isolates in A Chinese Tertiary Hospital.